Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARDS: LNA043 in Symptomatic Knee Osteoarthritis
jRCT2031210160Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of LNA043 in knee osteoarthritis (OA) (5 arms), sponsored by Novartis. Primary endpoint: Change from baseline in cartilage thickness in the central medial tibiofemoral compartment (cMTFC). Started Jul 2021; status: completed.
02
Drugs
LNA043
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2031210160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210160.